

CONTENTS VOL. 15, No. 1, 1996

HEAD AND NECK TUMORS

Overview

Head and neck tumors

W.K. Hong

1-2

Molecular staging of head and neck squamous carcinoma

J.A. Brennan and D. Sidransky

3-10

Biological staging of head and neck cancer and its role in developing effective treatment strategies

W.M. Lydiatt and S.P. Schantz

11-25

Cell, tissue and organ culture as *in vitro* models to study the biology of squamous cell carcinomas of the head and neck

P.G. Sacks

27-51

Molecular and cellular biomarkers for field cancerization and multistep process in head and neck tumorigenesis

V.A. Papadimitrakopoulou, D.M. Shin and W.K. Hong

53-76

Invasion and metastasis

D. Boyd

77-89

A possible role for human papillomaviruses in head and neck cancer

B.M. Steinberg and T.P. DiLorenzo

91-112

Clinical studies in head and neck cancer chemoprevention

P.M. Gonzalez and S.E. Benner

113-118

Programmed cell death and radioresistance

R.E. Meyn, L.C. Stephens and L. Milas

119-131

The clinical application of DNA content and kinetic parameters in the treatment of patients with squamous cell carcinomas of the head and neck

J.F. Ensley

133-141

Instructions for authors

143-144

CONTENTS VOL. 15, No. 2, June 1996

TUMOR ANGIOGENESIS

Overview

Commentaries on tumor angiogenesis: An introduction

R.S. Kerbel

145-147

What, if anything, is an angiogenic factor?

W. Risau

149-151

Similarities and differences between the vascular endothelial growth factor (VEGF) splice variants

G. Neufeld, T. Cohen, H. Gitay-Goren, Z. Poltorak, S. Tessler, R. Sharon,

S. Gengrinovitch and B.-Z. Levi

153-158

Biological properties of VEGF/VPF receptors

B.I. Terman and M. Dougher-Vermazen

159-163

Regulation of VEGF/VPF expression in tumor cells: Consequences for tumor growth and metastasis

K.P. Claffey and G.S. Robinson

165-176

Involvement of heparan sulfate and related molecules in sequestration and growth promoting activity of fibroblast growth factor

I. Vlodavsky, H.-Q. Miao, B. Medalion, P. Danagher and D. Ron

177-186

Cell adhesion molecules in angiogenesis

P.C. Brooks

187-194

Leukocyte-endothelial adhesion and angiogenesis in tumors

R.K. Jain, G.C. Koenig, M. Dellian, D. Fukumura, L.L. Munn and R.J. Melder

195-204

Tumor angiogenesis: A physiological process or genetically determined?

P.A. D'Amore and D.T. Shima

205-212

The role of angiogenic growth factors in breast cancer progression

F.G. Kern and M.E. Lippman

213-219

Bladder cancer angiogenesis, its role in recurrence, stage progression and as a therapeutic target

J.P. Crew, T.S. O'Brien and A.L. Harris

221-230

Treating cancer by inhibiting angiogenesis: New hopes and potential pitfalls

J. Rak and R.S. Kerbel

231-236

Gene therapy of malignant glioma via inhibition of tumor angiogenesis

K.H. Plate

237-240

Antiangiogenesis restricted tumor dormancy

L. Holmgren

241-245

A systems approach to cancer therapy

B.A. Teicher

247-272

Liver endothelial cells: Participation in host response to lymphoma metastasis

V. Umansky, M. Rocha and V. Schirrmacher

273-279

Instructions for authors

281-282

CONTENTS VOL. 15, No. 3, September 1996

GENE THERAPY OF CANCER

Gene therapy for cancer – in the dock, blown off course or full speed ahead? R.C. Vile	283–286
Antisense approaches to the gene therapy of cancer – 'Recnac' I. Gibson	287–299
Direct cell killing by suicide genes L.-A. Martin and N.R. Lemoine	301–316
Immunotherapy I: Cyclosine gene transfer strategies M.P. Colombo and G. Forni	317–328
Immunotherapy II: Antigens, receptors and costimulation P.F. Searle and L.S. Young	329–349
Immunotherapy III: Combinatorial molecular immunotherapy – a synthesis and suggestions R.G. Vile and H. Chong	351–364
Chemoprotection of normal tissues by transfer of drug resistance gene J.A. Rafferty, I. Hickson, N. Chinnasamy, L.S. Lashford, G.P. Margison, T.M. Dexter and L.J. Fairbairn	365–383
Vectors for cancer gene therapy J. Zhang and S.J. Russell	385–401
<i>Overview</i>	
Gene therapy for cancer, the course ahead R.G. Vile	403–410
Instructions for authors	411–412

INTERMEDIATE FILAMENTS

Intermediate filaments	413-416
M.J.C. Hendrix	
Intermediate filaments as dynamic structures	417-428
M.W. Klymkowsky	
Implications of intermediate filament protein phosphorylation	429-444
Nam-On Ku, Jian Liao, Chih-Fong Chou and M. Bishr Omary	
Oncogenic regulation and function of keratins 8 and 18	445-471
R.G. Oshima, H. Baribault and C. Caulin	
Intermediate filament expression in prostate cancer	473-482
R.B. Nagle	
Intermediate filaments in the nervous system: implications in cancer	483-497
Chung-Liang Ho, Ronald K.H. Liem	
Multiple drug resistance and intermediate filaments	499-506
A.E. Cress, W.S. Dalton	
Role of intermediate filaments in migration, invasion and metastasis	507-525
M.J.C. Hendrix, E.A. Seftor, Yi-Wen Chu, K.T. Trevor and R.E.B. Seftor	
Volume contents	527-530
Instructions for authors	531-532

